Metabolic and Genetic Determinants of Glucose Shape After Oral Challenge in Obese Youths: A Longitudinal Study.
Adolescent
Alleles
Child
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ genetics
Female
Genetic Predisposition to Disease
Genotype
Glucose
/ metabolism
Glucose Intolerance
/ genetics
Glucose Tolerance Test
Humans
Insulin Secretion
/ genetics
Insulin-Secreting Cells
/ metabolism
Longitudinal Studies
Male
Pediatric Obesity
/ genetics
Prediabetic State
/ genetics
Time Factors
Transcription Factor 7-Like 2 Protein
/ metabolism
Young Adult
TCF7L2
pediatric obesity
prediabetes
time to glucose peak
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 02 2020
01 02 2020
Historique:
received:
18
09
2019
accepted:
15
11
2019
entrez:
24
1
2020
pubmed:
24
1
2020
medline:
25
9
2020
Statut:
ppublish
Résumé
The time-to-glucose-peak following the oral glucose tolerance test (OGTT) is a highly reproducible marker for diabetes risk. In obese youths, we lack evidence for the mechanisms underlying the effects of the TCF7L2 rs7903146 variant on glucose peak. We analyzed the metabolic phenotype and the genotype for the TCF7L2 rs7903146 in 630 obese youths with normal (NGT) and impaired (IGT) glucose tolerance. Participants underwent a 3-hour, 9-point OGTT to estimate, using the oral minimal model, the disposition index (DI), the static (φstatic) and dynamic (φdynamic) components β-cell responsiveness and insulin sensitivity (SI). In a subgroup (n = 241) longitudinally followed for 2 years, we estimated the effect of time-to-glucose-peak on glucose tolerance change. Participants were grouped into early (<30 minutes) and late (≥30 minutes) glucose peakers. A delayed glucose peak was featured by a decline in φstatic (P < .001) in the absence of a difference in φdynamic. The prevalence of T-risk allele for TCF7L2 rs7903146 variant significantly increased in the late peak group. A lower DI was correlated with higher glucose concentration at 1 and 2 hours, whereas SI was inversely associated with 1-hour glucose. Glucose peak <30 minutes was protective toward worsening of glucose tolerance overtime (odds ratio 0.35 [0.15-0.82]; P = .015), with no subjects progressing to NGT or persisting IGT, in contrast to the 40% of progressor in those with late glucose peak. The prevalence of T-risk allele for the TCF7L2 rs7903146 prevailed in the late time-to-glucose peak group, which in turn is associated with impaired β-cell responsiveness to glucose (φ), thereby predisposing to prediabetes and diabetes in obese youths.
Identifiants
pubmed: 31972003
pii: 5714814
doi: 10.1210/clinem/dgz207
pmc: PMC6977541
pii:
doi:
Substances chimiques
TCF7L2 protein, human
0
Transcription Factor 7-Like 2 Protein
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK114504
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK111038
Pays : United States
Organisme : NICHD NIH HHS
ID : K24 HD001464
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK045735
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD028016
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD040787
Pays : United States
Informations de copyright
© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Diabetes Care. 2018 Jan;41(Suppl 1):S152-S153
pubmed: 29222386
Diabetes. 2001 Jan;50(1):150-8
pubmed: 11147781
Diabetes. 2014 Apr;63(4):1203-13
pubmed: 24651807
Am J Physiol Endocrinol Metab. 2010 Jun;298(6):E1115-21
pubmed: 20179243
Diabetes Obes Metab. 2019 May;21(5):1191-1198
pubmed: 30663201
Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E1-E15
pubmed: 17341552
J Clin Endocrinol Metab. 2010 Jul;95(7):3360-7
pubmed: 20444913
Diabetes. 2012 Mar;61(3):606-14
pubmed: 22315322
J Endocr Soc. 2018 May 07;2(6):547-562
pubmed: 29942919
Diabetes. 2005 Nov;54(11):3265-73
pubmed: 16249454
Diabetes Care. 2005 Apr;28(4):902-9
pubmed: 15793193
Diabetologia. 2015 Jun;58(6):1354-62
pubmed: 25762205
Diabetes. 2010 Feb;59(2):479-85
pubmed: 19934000
Diabetes Care. 2009 Sep;32(9):1583-8
pubmed: 19587364
Diabetologia. 2015 Jan;58(1):87-97
pubmed: 25292440
N Engl J Med. 2006 Jul 20;355(3):241-50
pubmed: 16855264
J Clin Invest. 2007 Aug;117(8):2155-63
pubmed: 17671651
J Clin Endocrinol Metab. 2008 Nov;93(11):4231-7
pubmed: 18713820
Diabetes Care. 2011 Sep;34(9):2033-40
pubmed: 21750275
Nat Genet. 2006 Mar;38(3):320-3
pubmed: 16415884
Physiol Rev. 2007 Oct;87(4):1409-39
pubmed: 17928588
Diabetes Care. 2017 Aug;40(8):1082-1089
pubmed: 28611053
Pediatr Diabetes. 2018 Oct;19 Suppl 27:28-46
pubmed: 29999228
Diabetes. 2017 Feb;66(2):241-255
pubmed: 27980006
Am J Physiol Endocrinol Metab. 2004 Oct;287(4):E637-43
pubmed: 15138152
Diabetes Care. 2016 Aug;39(8):1431-9
pubmed: 27293201
Diabetes. 2005 Jan;54(1):166-74
pubmed: 15616025
N Engl J Med. 2005 Oct 6;353(14):1454-62
pubmed: 16207847
Diabetes Care. 2018 Mar;41(3):554-561
pubmed: 29326107
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
Pediatr Diabetes. 2011 Sep;12(6):572-9
pubmed: 21466647
Diabetes Care. 2014 Feb;37(2):475-82
pubmed: 24062323
Diabetes Care. 2018 Aug;41(8):1740-1748
pubmed: 29853473
Clin Endocrinol (Oxf). 2017 Nov;87(5):484-491
pubmed: 28681942
Diabetes. 2002 Feb;51 Suppl 1:S212-20
pubmed: 11815482
Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E954-9
pubmed: 16014353
JAMA. 2007 Jun 27;297(24):2697-704
pubmed: 17595270
Diabetes. 2006 Dec;55(12):3536-49
pubmed: 17130502
Diabetol Metab Syndr. 2018 Apr 26;10:37
pubmed: 29736187
N Engl J Med. 2002 Mar 14;346(11):802-10
pubmed: 11893791
Lancet Child Adolesc Health. 2018 Oct;2(10):726-735
pubmed: 30236381
J Mol Med (Berl). 2007 Jul;85(7):777-82
pubmed: 17476472
Diabetes Care. 2013 Jun;36(6):1681-6
pubmed: 23315601